Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Avital Bareket-Samish"'
Autor:
Shlomit S. Shachar, Michelle Leviov, Rinat Yerushalmi, Karen Drumea, Margarita Tokar, Lior Soussan-Gutman, Avital Bareket-Samish, Amir Sonnenblick, Noa Ben-Baruch, Ella Evron, Einav Nili Gal-Yam, Shani Paluch-Shimon, Gil Bar-Sela, Hadar Goldvaser, Salomon M. Stemmer
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second BC, who underwent 21-gene testing both times. It
Externí odkaz:
https://doaj.org/article/3bcf6bdee0c84eafb59930d692223e0a
Autor:
Ofer Rotem, Idit Peretz, Michelle Leviov, Iryna Kuchuk, Amit Itay, Margarita Tokar, Shani Paluch-Shimon, Ofra Maimon, Rinat Yerushalmi, Karen Drumea, Ella Evron, Amir Sonnenblick, Einav Gal-Yam, Hadar Goldvaser, Yosef Samih, Rotem Merose, Avital Bareket-Samish, Lior Soussan-Gutman, Salomon M. Stemmer
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-8 (2023)
Abstract Data on adjuvant chemotherapy (CT) benefit in ER + HER2‒ early-stage breast cancer (EBC) patients with Recurrence Score (RS) 26-30 are limited. This real-world study evaluated the relationships between the RS, adjuvant treatments, and outc
Externí odkaz:
https://doaj.org/article/ee418dc5761c458bb5099fc02f2cafa0
Publikováno v:
Biomedicines, Vol 12, Iss 4, p 848 (2024)
Namodenoson (CF102) is a small, orally available, anti-inflammatory, and anti-cancer drug candidate currently in phase 2B trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH; formerly known as non-alcoholic steatohepatit
Externí odkaz:
https://doaj.org/article/859333e70f804250ab4c3e44b0d54c17
Publikováno v:
Biomolecules, Vol 13, Iss 11, p 1584 (2023)
Namodenoson, an A3 adenosine receptor (A3AR) agonist, is currently being used in a phase III trial in advanced liver cancer. We examined the anti-growth effect of namodenoson on pancreatic carcinoma cells and investigated the molecular mechanism invo
Externí odkaz:
https://doaj.org/article/41b12f1bcdb04db1afcdc6209e0310ff
Autor:
Noa Eliakim-Raz, Haim Ben-Zvi, Erez Bar-Haim, Salomon M Stemmer, Amos Stemmer, Yaara Leibovici-Weisman, Asaf Ness, Muhammad Awwad, Nassem Ghantous, Noam Erez, Avital Bareket-Samish, Adva Levy-Barda, Neta Moskovits
Publikováno v:
BMJ Open, Vol 12, Iss 8 (2022)
Objective To evaluate the durability of response 3 months after the third BNT162b2 vaccine in adults aged 60 years and older.Design Prospective cohort study.Setting Single tertiary centre.Participants Healthcare workers/family members aged ≥60 year
Externí odkaz:
https://doaj.org/article/f513cbeb41f04c289d824dc17e51979d
Autor:
Shlomit S, Shachar, Gil, Bar-Sela, Avivit, Peer, Mor Tal, Moskovitz, Avital, Bareket-Samish, Jessica, Epstein, Mira, Wollner, Itamar, Shafran, Amit, Boukal, Grant R, Williams
Publikováno v:
Journal of Geriatric Oncology. 13:1203-1207
We investigated the associations among frailty, as determined via the comprehensive geriatric assessment (CGA), muscle measures (i.e., sarcopenia), and treatment-related toxicity in older adults with cancer in Israel.This prospective cohort study enr
Autor:
Rinat Yerushalmi, Adi Pomerantz, Ron Lewin, Shani Paluch-Shimon, Lior Soussan-Gutman, Frederick Baehner, Hillary Voet, Avital Bareket-Samish, Inbal Kedar, Yael Goldberg, Tamar Peretz-Yablonski, Luna Kadouri
Publikováno v:
Cancer Research. 83:P3-05
Background: The RS assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in ER+ HER2-negative early-stage breast cancer (BC). It is offered to pts irrespective of BRCA1/2 status. We compared RS results, single-gene expression and
Autor:
Ella Itzhaki, Eva Chausky‐Barzakh, Ayelet Atkins, Avital Bareket‐Samish, Salomon M. Stemmer, Shlomo Margel, Neta Moskovits
Publikováno v:
Advanced Therapeutics.
Autor:
Pnina Fishman, Salomon M. Stemmer, Avital Bareket-Samish, Michael H. Silverman, William D. Kerns
Publikováno v:
Purinergic Signalling.
The A3 adenosine receptor (A3AR) is over-expressed in human hepatocellular carcinoma (HCC) cells. Namodenoson, an A3AR agonist, induces de-regulation of the Wnt and NF-kB signaling pathways resulting in apoptosis of HCC cells. In a phase I healthy vo
Autor:
Shlomit Strulov Shachar, Michelle Leviov, Rinat Yerushalmi, Karen Drumea, Margarita Tokar, Lior Soussan-Gutman, Avital Bareket-Samish, Amir Sonnenblick, Noa Efrat Ben-Baruch, Shani Paluch-Shimon, Gil Bar Sela, Salomon M Stemmer
Publikováno v:
Cancer Research. 82:P1-08
Background: The first invasive disease-free survival event in patients (pts) with estrogen receptor (ER)+ early-stage breast cancer (BC) is often contralateral BC, as reflected in the TAILORx data. We analyzed the CHS registry to study differences in